"Staging the aging" when considering androgen deprivation therapy for older men with prostate cancer

Journal of Clinical Oncology

Volumn 27, Issue 21, 2009, Pages 3420-3422

  Dale, William ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; TESTOSTERONE;

AGED; AGING; ANDROGEN DEPRIVATION THERAPY; CANCER GRADING; CANCER STAGING; CARDIOVASCULAR DISEASE; COMORBIDITY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; EDITORIAL; FATIGUE; HEART INFARCTION; HOT FLUSH; HUMAN; INSULIN RESISTANCE; LIFE EXPECTANCY; LIPID BLOOD LEVEL; MALE; OSTEOPOROSIS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RISK ASSESSMENT; SIDE EFFECT; SUDDEN DEATH; WEAKNESS; ELDERLY CARE; MORTALITY; PHYSIOLOGY; PROSTATE TUMOR;

AGING; ANDROGEN ANTAGONISTS; FATIGUE; HEALTH SERVICES FOR THE AGED; HOT FLASHES; HUMANS; MALE; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 70249105062     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.9104     Document Type: Editorial

References (23)

1. Huggins C, Hodges CV: Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J Urol 168:9-12, 2002
2. Huggins C, Stevens RE Jr, Hodges CV: Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43:209-223, 1941
3. Bylow K, Mohile SG, Stadler WM, et al: Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer? Cancer 110:2604-2613, 2007
4. Mohile SG, Mustian K, Bylow K, et al: Management of complications of androgen deprivation therapy in the older man. Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2008.09.004 [epub ahead of print on October 24, 2008]
5. Loblaw DA, Virgo KS, Nam R, et al: Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2007 update of an American Society of Clinical Oncology Practice Guideline. J Clin Oncol 25:1596-1605, 2007
6. Lu-Yao GL, Albertsen PC, Moore DF, et al: Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 300:173-181, 2008
7. Jemal A, Tiwari RC, Murray T, et al: Cancer Statistics, 2004. CA Cancer J Clin 54:8-29, 2004
8. Extermann M, Hurria A: Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25:1824-1831, 2007
9. Alibhai SMH, Gogov S, Allibhai Z: Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: A systematic literature review. Crit Rev Oncol Hematol 60:201-215, 2006
10. Smith MR: Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer. Cancer Metastasis Rev 21:159-166, 2002
11. Mohile S, Bylow K, Dale W, et al: A pilot study of the Vulnerable Elders Survey-13 (VES-13) as compared to the Comprehensive Geriatric Assessment (CGA) for identifying disability in older prostate cancer patients receiving androgen ablation. Cancer 109:802-810, 2007
12. Shahinian VB, Kuo Y-F, Freeman JL, et al: Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med 166:465-471, 2006
13. Tsai HK, D'Amico AV, Sadetsky N, et al: Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99:1516-1524, 2007
14. Ketchandji M, Kuo Y-K, Shahinian VB, et al: Cause of death in older men after the diagnosis of prostate cancer. J Am Geriatr Soc 57:24-30, 2009
15. Keating NL, O'Malley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24:4448-4456, 2006
16. D'Amico AV, Denham JW, Crook J, et al: Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25:2420-2425, 2007
17. Efstathiou JA, Bae K, Shipley WU, et al: Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: Analysis of RTOG 92-02. Eur Urol 54:816-823, 2008
18. Roach M III, Bae K, Speight J, et al: Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 26:585-591, 2008
19. Alibhai SMH, Duong-Hua M, Sutradhar R, et al: Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 27:3452-3458, 2009
20. Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002
21. De La Taille A, Zerbib M, Conquy S, et al: Intermittent androgen suppression in patients with prostate cancer. BJU Int 91:18-22, 2003
22. Rodin MB, Mohile SG: A practical approach to geriatric assessment in oncology. J Clin Oncol 25:1936-1944, 2007
23. Dale W, Hemmerich J, Bylow K, et al: Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: A prospective cohort study. J Clin Oncol 27:1557-1563, 2009